Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1994 1
1997 1
2003 1
2004 1
2008 1
2013 1
2014 1
2015 1
2017 2
2018 2
2019 1
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Physiological and training characteristics of recreational marathon runners.
Gordon D, Wightman S, Basevitch I, Johnstone J, Espejo-Sanchez C, Beckford C, Boal M, Scruton A, Ferrandino M, Merzbach V. Gordon D, et al. Open Access J Sports Med. 2017 Nov 24;8:231-241. doi: 10.2147/OAJSM.S141657. eCollection 2017. Open Access J Sports Med. 2017. PMID: 29200895 Free PMC article.

RESULTS: Training frequency was shown to be significantly greater for the 2.5-3 h group compared to the 3.5-4 h runners (P < 0.001) and >4.5 h group (P = 0.004), while distance per session (km.session(-1)) was significantly greater for the 2.5-3 h

RESULTS: Training frequency was shown to be significantly greater for the 2.5-3 h group compared to the 3.5-4 h runners (P &lt …
Rab29 activation of the Parkinson's disease-associated LRRK2 kinase.
Purlyte E, Dhekne HS, Sarhan AR, Gomez R, Lis P, Wightman M, Martinez TN, Tonelli F, Pfeffer SR, Alessi DR. Purlyte E, et al. EMBO J. 2018 Jan 4;37(1):1-18. doi: 10.15252/embj.201798099. Epub 2017 Dec 6. EMBO J. 2018. PMID: 29212815 Free PMC article.
SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS.
Mueller C, Berry JD, McKenna-Yasek DM, Gernoux G, Owegi MA, Pothier LM, Douthwright CL, Gelevski D, Luppino SD, Blackwood M, Wightman NS, Oakley DH, Frosch MP, Flotte TR, Cudkowicz ME, Brown RH Jr. Mueller C, et al. N Engl J Med. 2020 Jul 9;383(2):151-158. doi: 10.1056/NEJMoa2005056. N Engl J Med. 2020. PMID: 32640133
Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers.
Cammack AJ, Atassi N, Hyman T, van den Berg LH, Harms M, Baloh RH, Brown RH, van Es MA, Veldink JH, de Vries BS, Rothstein JD, Drain C, Jockel-Balsarotti J, Malcolm A, Boodram S, Salter A, Wightman N, Yu H, Sherman AV, Esparza TJ, McKenna-Yasek D, Owegi MA, Douthwright C; Alzheimer's Disease Neuroimaging Initiative; McCampbell A, Ferguson T, Cruchaga C, Cudkowicz M, Miller TM. Cammack AJ, et al. Neurology. 2019 Oct 22;93(17):e1605-e1617. doi: 10.1212/WNL.0000000000008359. Epub 2019 Oct 2. Neurology. 2019. PMID: 31578300 Free PMC article.
Zones of exocytotic release on bovine adrenal medullary cells in culture.
Schroeder TJ, Jankowski JA, Senyshyn J, Holz RW, Wightman RM. Schroeder TJ, et al. J Biol Chem. 1994 Jun 24;269(25):17215-20. J Biol Chem. 1994. PMID: 8006030 Free article.
In this small domain, point-source release and diffusional broadening would result in narrow spikes (Schroeder, T. J., Jankowski, J. A., Kawagoe, K. T., Wightman, R. M., Lefrou, C., and Amatore, C. (1992) Anal. Chem. 64, 3077-3083), a feature not seen in the data. . …
In this small domain, point-source release and diffusional broadening would result in narrow spikes (Schroeder, T. J., Jankowski, J. A., Kaw …
A role for presynaptic mechanisms in the actions of nomifensine and haloperidol.
Garris PA, Budygin EA, Phillips PE, Venton BJ, Robinson DL, Bergstrom BP, Rebec GV, Wightman RM. Garris PA, et al. Neuroscience. 2003;118(3):819-29. doi: 10.1016/s0306-4522(03)00005-8. Neuroscience. 2003. PMID: 12710989
A positive temporal association was found between [DA](max) and motor activation following nomifensine (r=0.99) and a negative correlation was found between [DA](max) and catalepsy following haloperidol (r=-0.96) in the second experiment. ...
A positive temporal association was found between [DA](max) and motor activation following nomifensine (r=0.99) and a negative correl …
Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats.
Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM. Cheer JF, et al. J Neurosci. 2004 May 5;24(18):4393-400. doi: 10.1523/JNEUROSCI.0529-04.2004. J Neurosci. 2004. PMID: 15128853 Free PMC article.
Intravenous administration of the central cannabinoid (CB1) receptor agonist, R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-(1-naphthalenyl) methanone mesylate, dose-dependently produced catalepsy, decreased locomotion, and reduce …
Intravenous administration of the central cannabinoid (CB1) receptor agonist, R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrro …
15 results